13F Holdings
中文EN

CMPS COMPASS Pathways plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1816590 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY14.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-296.5%
ROA-68.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets72.6%
Debt / equity0.36x
Current ratio1.50x
Interest coverage-35.36x

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$118.44M$119.04M$87.52M$65.05M$44.03M
SG&A expense$60.60M$59.17M$49.40M$45.35M$39.19M
Operating income-$179.04M-$178.21M-$136.92M-$110.40M-$83.22M
Interest expense$4.52M$4.48M$2.20M$0$0
Pretax income-$290.33M-$153.53M-$117.68M-$91.10M-$71.54M
Income tax-$2.47M$1.59M$780,000$408,000$199,000
Net income-$287.86M-$155.12M-$118.46M-$91.50M-$71.74M
EBITDA-$178.82M-$177.97M-$136.68M-$110.07M-$83.05M
EPS (basic)-3.08-2.30-2.32-2.16-1.79
EPS (diluted)-3.08-2.30-2.32-2.16-1.79
Weighted avg. shares (diluted)93.50M67.48M51.03M42.44M40.00M
Balance sheet
Cash & equivalents$149.61M$165.47M$220.64M$143.38M$273.24M
Current assets$191.49M$201.29M$261.30M$191.65M$295.30M
PP&E, net—$189,000$423,000$617,000$398,000
Total assets$210.35M$213.67M$275.99M$197.29M$300.90M
Current liabilities$247.79M$34.02M$19.60M$15.60M$15.11M
Short-term debt$17.52M$5.51M$0——
Long-term debt$14.11M$24.65M$28.76M$0—
Total debt$31.63M$30.16M$28.76M$0—
Total liabilities$263.20M$58.97M$50.24M$16.01M$16.49M
Shareholders' equity-$52.85M$154.69M$225.74M$181.28M$284.41M
Net debt-$117.97M-$135.31M-$191.88M-$143.38M—
Shares outstanding96.09M68.55M61.94M——
Cash flow statement
Operating cash flow-$157.24M-$119.19M-$97.38M-$105.45M-$67.75M
Capital expenditure—$0$66,000$596,000$334,000
Free cash flow—-$119.19M-$97.44M-$106.05M-$68.08M
Investing cash flow—$0-$64,000-$596,000-$334,000
Financing cash flow$140.71M$63.82M$173.83M$1.04M$156.65M
Depreciation & amortization$216,000$233,000$242,000$330,000$175,000
Stock-based compensation$13.59M$19.52M$17.28M$13.12M$8.64M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.